Publications & Presentations

This study, a collaboration with Dr. Salazar’s lab at the University of Murcia in Spain, describes the beneficial effects of PRALICIGUAT and EMPAGLIFLOZIN on the pathophysiology associated with prolonged exposure of hypertensive rats with altered renal development (ARDev) to a high fat diet (HFD). Combined administration of PRALICIGUAT and EMPAGLIFLOZIN leads to a greater improvement of the cardiovascular (including arterial pressure), renal (including renal vascular resistance), and metabolic dysfunction (including glucose tolerance, body weight gain, and insulin resistance index) in these ARDev rats on HFD than the treatment with either PRALICIGUAT or EMPAGLIFLOZIN alone.

This research describes the potential clinical utility of olinciguat, based on studies investigating its pharmacokinetics, tissue distribution, and pharmacologic effects in preclinical models. In nonclinical models, olinciguat relaxed human vascular smooth muscle cells and was a potent inhibitor of vascular smooth muscle proliferation in vitro and lowered blood pressure in vivo. In preclinical animal models of disease, olinciguat was cardioprotective in the Dahl rat salt-sensitive hypertensive heart failure model. In the rat ZSF1 model of diabetic nephropathy and metabolic syndrome, olinciguat was renoprotective and associated with lower circulating glucose, cholesterol, and triglycerides. In a mouse TNFα-induced inflammation model, olinciguat treatment was associated with lower levels of endothelial and leukocyte-derived soluble adhesion molecules.

This journal article characterizes the effects of Cyclerion’s systemic sGC stimulator, praliciguat, in models of nonalcoholic steatohepatitis (NASH), identifying key target cells and downstream signaling pathways responsible for the observed pharmacology. These data support the potential utility of sGC stimulation as a promising mechanism in the treatment of NASH and fibrotic liver diseases.

In this preclinical study, olinciguat – either alone or in combination with the approved sickle cell treatment hydroxyurea – improved blood flow and reduced leukocyte/endothelial cell interactions. In patients with sickle cell disease, these leukocyte/endothelial cell interactions can block small blood vessels, interrupting normal blood flow and oxygen delivery and causing complications such as vaso-occlusive crises, organ damage, and daily symptoms.

This poster provides an overview of the patient and clinician interviews and the literature research that informed the development of Cyclerion’s patient-reported outcomes (PRO) tool. This PRO tool is designed to measure the symptoms that patients with sickle cell disease indicated are most important and relevant to their daily lives. Cyclerion is using this instrument in the ongoing STRONG SCD study.

This preclinical study provides insights into praliciguat’s mechanism of action by characterizing the nature of its high affinity binding to sGC.

Data from this preclinical study suggest that praliciguat may have positive effects on key metabolic parameters.

This article provides an overview of the preclinical profile of praliciguat, known as IW-1973 at the time of publication.

This oral presentation further elucidates the results of the Phase 2a study of praliciguat in patients with diabetes and hypertension by sharing the results of post-hoc subgroup analyses by concomitant medication use and baseline blood pressure levels.

This oral presentation, delivered at the American Diabetes Association 78^th Scientific Sessions, summarizes the results from an exploratory Phase 2a clinical study of praliciguat in patients with diabetes and hypertension.

The results of a Phase 1b study of praliciguat in healthy volunteers support its evaluation for the treatment of conditions associated with deficient nitric oxide signaling.

This research describes the effects of olinciguat on markers of vascular inflammation in a preclinical model.

This research summarizes the data from a Phase 1b multiple-ascending-dose study with olinciguat in healthy volunteers. Pharmacokinetic parameters, including volume of distribution, are reported in the abstract and the graphic below.